Legal & General Group
AARD

Legal & General Group’s Aardvark Therapeutics AARD Stock Holding History

Legal & General Group’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,143
Closed -$4.31K – 3563
2026
Q1 		$4.31K Sell
1,143
-145
-11% -$1.5K ﹤0.01% 3302
2025
Q4 		$16.9K Buy
1,288
+701
+119% +$8.75K ﹤0.01% 3099
2025
Q3 		$7.8K Hold
587
– – ﹤0.01% 3330
2025
Q2 		$7.94K Buy
+587
New +$6.05K ﹤0.01% 3339

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Legal & General Group's AARD Position: Q2 2026 in Review

Legal & General Group sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 1,143 shares — an estimated $4.31K sold.

Legal & General Group first reported a position in AARD in Q2 2025 and held it in 4 quarters. The position peaked at $16.9K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Legal & General Group reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Legal & General Group sold 1,143 Aardvark Therapeutics shares in Q2 2026, an estimated $4.31K.
  • Legal & General Group first reported a position in Aardvark Therapeutics in Q2 2025 and held it in 4 quarters.
  • Legal & General Group's Aardvark Therapeutics position peaked at $16.9K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.